Sequana Medical NV | August 29, 2022
Sequana Medical NV a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. Ms. Clyde is a highly experienced global business executive with an exceptional understanding and track record of successfully navigating health economics and reimbursement in the medical device industry. The Company also announces that Erik Amble will step down as a member of the Board of Directors after the board meeting of 7 September 2022, and will continue to attend the meetings as a board observer in a non-voting capacity.
“Alex will be a critical member of our Board as Sequana Medical prepares to expand commercialization of the alfapump. Her experience from more than 25 years at Medtronic, a global leader in healthcare technology, and her understanding of healthcare systems around the world will prove invaluable as we continue to grow our business and seek to transform the care of liver disease and heart failure. On behalf of the Board, I would also like to thank Erik for his tremendous contributions to the Company and we are pleased to still have him as an observer on the Board.”
Pierre Chauvineau, Chairman of the Board at Sequana Medical
Ms. Clyde added: “I believe that both of Sequana Medical’s programs – the alfapump® and DSR® therapy – have the potential to deliver tremendous benefit to patients and the healthcare community. In these two large and growing patient populations, liver disease and heart failure, drug-resistant fluid overload is a significant and burdensome challenge with limited effective treatment options. Sequana Medical is in an exciting position to help these patients and reduce the burden of disease. I look forward to working with the Board and management team to help the Company reach its potential.”
Mr. Amble added: “At this time in the Company’s evolution, it is critically important that the Board brings expertise to help guide the Company’s commercial readiness activities in North America. With Doug and Alex now on the Board, I am confident that the Board is well positioned to guide Sequana Medical as it enters a period of potential exponential growth. It’s been a pleasure to work with Sequana Medical’s Board and management team for more than 15 years and I look forward to continuing my involvement as a Board observer.”
Ms. Clyde is Senior Vice President of Global Health Economics, Policy, and Reimbursement for Medtronic plc. In this role, she leads a global function of more than 300 reimbursement and health economics professionals and provides company-wide leadership on health and payment policy. She is a member of the Duke Margolis Value-Based Payment and Innovative Technology Consortium, the Health Technology Assessment International (HTAi) Policy Forum, and the Advisory Board for the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center. She is a former member of the Health Care Payment Learning and Action Network’s Guiding Committee which is charged by the US Secretary of Health and Human Services with accelerating the health care system’s transition to alternative payment models (APMs) by combining the innovation, power, and reach of the public and private sectors. She has also participated in various Centers for Medicare and Medicaid Services technical advisory councils as well as other private and public sector initiatives to improve value in health care. Alex graduated from Colgate University with a B.A. in Economics and from Harvard University with a M.S. in Health Policy and Management.
Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life.
Firmament and Panacea Healthcare Solutions | August 24, 2022
Firmament, a leading provider of structured equity capital solutions to small- and medium-sized enterprises, announced a growth capital investment in Panacea Healthcare Solutions ("Panacea"). Panacea provides strategic pricing, price transparency, chargemaster, compliance, and revenue integrity software and consulting services to healthcare companies across the full continuum of care. Firmament's investment will fuel innovation and expand Panacea's product suite through the acquisition of Holliday & Associates and First Healthcare Compliance. The combined company will be a leading provider of healthcare revenue integrity and compliance software and services to over 600 hospitals, health systems, physician practices, and accountable care organizations across the United States.
The executive management teams of Panacea, Holiday & Associates, and First Healthcare Compliance will remain in place, together with the majority of their former shareholders. Panacea CEO Frederick Stodolak will continue to serve as Chief Executive Officer of the combined platform and will expand his role to become an active Chairman of the Board.
Stodolak stated, "We are proud to partner with Firmament and are excited for our future growth and continued product innovation. With the acquisition of Holliday & Associates, we are excited that our customers will benefit from access to a comprehensive suite of chargemaster software tools from a single vendor. Furthermore, we look forward to expanding First Healthcare Compliance's popular learning platform to leverage Panacea's expertise in inpatient, outpatient, and physician coding and compliance."
"We have been partners with Panacea for many years and are thrilled to formally combine our two companies. With this step, our clients will benefit greatly as we integrate to become one of the industry's most comprehensive providers of revenue integrity software solutions."
Rosemary Holliday, Managing Partner at Holliday & Associates
"First Healthcare Compliance clients will benefit from the wide array of coding compliance and revenue integrity software solutions that Panacea offers," Julie Sheppard, President of First Healthcare Compliance, commented. "Our team looks forward to continuing to support our amazing clientele through expanded product offerings and continued investments into our compliance platform."
Green Campbell, Vice President at Firmament stated, "Healthcare providers today are overburdened by complex coding, pricing, and compliance rules. Panacea's price transparency, strategic pricing, coding, and compliance solutions sit at the forefront of the most relevant regulations impacting the healthcare industry today. We are proud to partner with the teams at Panacea, Holiday & Associates, and First Healthcare Compliance to support their continued growth and investments in cutting edge software and tech-enabled services."
About Panacea Healthcare Solutions
Panacea provides software and tech-enabled services that help healthcare organizations improve their revenue integrity, coding, and compliance with front-line expertise in mid-revenue cycle management. In an era where 95% of provider revenue is driven by accurate coding and defensible yet optimal pricing, clients trust Panacea to deliver unparalleled value in strategic pricing, price transparency, chargemaster, compliance, and revenue integrity solutions.
Firmament provides structured equity capital solutions to small- and medium-sized enterprises. Firmament is a value-added partner to entrepreneurs, management teams and business owners and curates solutions by deploying versatile capital in a user-friendly way. Firmament concentrates on software and services businesses with significant scaling potential in the healthcare, logistics, wellness and environmental sectors. With offices across the United States and in the United Kingdom, Firmament is focused on turning small business into big business.
Johnson & Johnson | September 21, 2022
Johnson & Johnson opened its San Francisco Bay Campus, a state-of-the-art Research & Development facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the Company into the Bay Area innovation ecosystem to strengthen and increase collaborations with innovators to accelerate growth.
“Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions. On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.”
Joaquin Duato, Chief Executive Officer, Johnson & Johnson
The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies, novel treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning. Co-locating expertise at the site will enable the expansion of the Company’s world-class discovery engine and industry-leading pipeline.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” said James Merson, Ph.D., Site Head, San Francisco Bay Campus and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC.
The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystem since 2014. The San Francisco Bay Campus, along with the Company’s JLABS @ South San Francisco, will continue to enable the Company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the Company will increase its focus on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health.
Building on Johnson & Johnson’s long-standing commitment to use its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, reinforcing the Company’s pledge to be responsible stewards in creating a healthy, more sustainable future. The aim is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the most widely used green building rating system in the world.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health.
About Johnson & Johnson Technology
Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from any location, our digital tools infuse our products with novelty, dexterity, and ease.
MCI Onehealth Technologies, Inc. | July 29, 2022
MCI Onehealth Technologies Inc. a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and MDClone, a digital health company and leader in synthetic data, are pleased to announce an advanced clinical intelligence offering for their global partners. This offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development.
“MCI’s collaboration with MDClone will provide our partners with greater access to high-value data-insights-as-a-service for an array of research, clinical and data science needs. Whether through MCI’s clinic network, international healthcare providers, or pharmaceutical, life sciences and biotech partners, our mutually enhanced insights will help to quickly translate healthcare data and research into improved health and quality of life for patients.”
Dr. Alexander Dobranowski, MD, Chief Executive Officer of MCI
The real-world patient health journeys that MCI’s tech-enabled network is able to capture offer a comprehensive picture to researchers, who can benefit from a fuller perspective. The partnership between MCI and MDClone will leverage MDClone’s technology to load, organize and protect MCI-generated patient data and use this data to help find insights to improve care. In addition, MCI and MDClone intend to work together to improve data collection and curation to better serve the needs of applied healthcare research.
MDClone offers clients robust, detailed data for thorough end-to-end, real-world analysis. Using the MDClone ADAMS Platform analytics tools and synthetic data capabilities, clinicians, researchers, and healthcare professionals can explore healthcare data more efficiently to accelerate real-world evidence processes. With synthetic data capabilities at the forefront, users can leverage self-service tools to access, analyze, and share information without privacy concerns. Additionally, the real-time identification and extraction of information about a specific population of interest allows users at healthcare systems to overcome some of the common barriers that can slow clinical data projects’ progress.
“We’re thrilled to partner with innovators like MCI in the healthcare and life science industries and beyond. Together, we can provide tailored clinical insights that meet clients’ needs, and from those insights, MDClone can generate synthetic data that researchers can use to better understand disease progression, enhance care delivery, and develop new products that can improve patient outcomes,” said Josh Rubel, Chief Operating Officer of MDClone.
In keeping with its objective to be a preeminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. The MDClone ADAMS Platform’s unique ability to convert datasets and cohorts of interest into synthetic files that are statistically comparable to the original data, but composed entirely of artificial patients, aids in broader and more secure access and opens the doors to third-party access and larger-scale research impact.
MCI’s audience for health insights continues to grow in Canada and will further benefit from access to MDClone’s global roster of top-tier health system and pharma relationships. The collaboration with MDClone will accelerate MCI’s entry into the clinical insights and analytics sectors in the United States of America and Israel, including potential access to headquarter-level decision-makers of global pharma and life science leaders.
“Through this commercial arrangement, we each have the benefit of immediate introduction to the active client rosters of the other, and we each gain a superior — and unique — offering to acquire new partners, fueling the expansion of MCI’s health insight services into international markets,” added Dr. Dobranowski.
MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada’s leading primary care networks with nearly 260 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company’s current roadmap.
MDClone offers an innovative, self-service data analytics environment powering exploration, discovery, and collaboration throughout healthcare ecosystems cross-institutionally and globally. The powerful underlying infrastructure of the MDClone ADAMS Platform allows users to overcome common barriers in healthcare in order to organize, access, and protect the privacy of patient data while accelerating research, improving operations and quality, and driving innovation to deliver better patient outcomes. Founded in Israel in 2016, MDClone serves major health systems, payers, and life science customers in the United States, Canada, and Israel.